Status:
COMPLETED
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
Lead Sponsor:
Mclean Hospital
Collaborating Sponsors:
Forest Laboratories
Conditions:
Binge Eating Disorder
Eligibility:
All Genders
16-65 years
Phase:
PHASE4
Brief Summary
We hypothesize that memantine may be a safe and effective treatment for moderate to severe binge eating disorder associated with obesity. During this 12-week, open-label, outpatient study, male and f...
Detailed Description
Binge eating disorder is a newly recognized disorder characterized by recurrent episodes of binge eating without extreme behaviors to lose weight characteristic of bulimia nervosa or anorexia nervosa ...
Eligibility Criteria
Inclusion
- Subjects may be male or female, 18-65 years old
- Diagnosis of binge eating disorder
- Subjects must have 3 or more binge days per week for the two weeks prior to the start of the study
- Subjects must have a BMI between 30 and 50 kg/m2
Exclusion
- Current or lifetime history of schizophrenia, other psychotic disorder, or bipolar disorder
- Subjects with a history of a personality disorder
- Subjects with clinically significant depression
- Subjects with substance use of dependence
- Subjects who are pregnant or lactating
- Subjects with a serious medical condition
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00330655
Start Date
May 1 2006
End Date
July 1 2007
Last Update
August 14 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Hospital
Belmont, Massachusetts, United States, 02478